Etoposide, Ara-C, and doxorubicin increase DR5 levels in HL-60 and Jurkat cells (A).

Following exposures of HL-60 and Jurkat cells with the indicated drug concentrations, DR5, DcR2, Apo-2L, Fas, Fas L, and β-actin levels were determined by immunoblot analyses (see “Results”). Effect of exposure intervals to Ara-C on DR5 levels of HL-60 cells (B). HL-60 cells were exposed to 1.0 μmol/L Ara-C for 6 hours. Cell lysate of untreated (lane 1), or drug-treated cells after 2 (lane 2), 4 (lane 3), 6 (lane 4), and 24 hours (of which 18 hours were in drug-free medium) (lane 5) were subjected to immunoblot analysis of DR5 levels (see “Results”). Levels of β-actin were used as the loading control. Effect of the dose of Ara-C on DR5 levels (C). HL-60 cells were exposed to different concentrations of Ara-C for 6 hours. Following this, immunoblot analysis of DR5 levels was performed; β-actin levels were used as the loading control.